Genmab A/S (OTCMKTS:GNMSF – Get Free Report) passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $281.01 and traded as high as $303.50. Genmab A/S shares last traded at $289.99, with a volume of 581 shares.
Genmab A/S Price Performance
The company’s fifty day moving average is $281.01 and its 200-day moving average is $232.99. The stock has a market cap of $19.16 billion, a PE ratio of 14.56 and a beta of 0.95.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $5.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.99 by $1.43. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $949.06 million.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
- Five stocks we like better than Genmab A/S
- Differences Between Momentum Investing and Long Term Investing
- 2 Ways to Trade Qualcomm Ahead of November’s Earnings
- What Are the U.K. Market Holidays? How to Invest and Trade
- Lululemon: 2 Signs the Bottom Is In, and 1 Sign It Isn’t
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Got 1K to Invest? These 3 Stocks Are Still Attractive Buys
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
